AB Science announces outcomes from masitinib phase 2 study on MS AB Research SA , a pharmaceutical company focusing on the research, development and commercialization of protein kinase inhibitors, announces the publication of results from the human phase 2 study of masitinib carried-out in the treating progressive multiple sclerosis. There is currently no satisfactory treatment for primary progressive multiple sclerosis or relapse-free of charge secondary progressive multiple sclerosis, which represent approximately 60 percent of patients identified as having multiple sclerosis https://tadalafilgen.com/ .